Thanks for Nodus-ing: Basilea hands off pre­clin­i­cal on­col­o­gy pro­gram for $248M in on­go­ing an­ti-in­fec­tives piv­ot

Looks like Basilea Phar­ma­ceu­ti­ca is get­ting clos­er to its fi­nal days as an on­col­o­gy com­pa­ny.

The Switzer­land-based Roche off­shoot said Thurs­day that it had sold …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER